Consensus Statement Regarding the Application of Biogen to Health Canada for Approval of Aducanumab

Alzheimer’s disease is a major cause of morbidity and mortality. Currently, there are no disease-modifying pharmacotherapies for this condition. Aducanumab, an amyloid beta-directed monoclonal antibody that targets aggregated forms of amyloid-beta in the brains of people with Alzheimer’s disease, ha...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Howard Chertkow, Kenneth Rockwood, David B. Hogan, Natalie Phillips, Manuel Montero-Odasso, Shabbir Amanullah, Sandra Black, Christian Bocti, Michael Borrie, Howard Feldman, Morris Freedman, Robin Hsiung, Andrew Kirk, Mario Masellis, Haakon Nygaard, Tarek Rajji, Louis Verret
Format:	Artigo
Język:	Inglês
Wydane:	Canadian Geriatrics Society 2021-12-01
Seria:	Canadian Geriatrics Journal
Hasła przedmiotowe:	aducanumab Alzheimer's disease drug therapy
Dostęp online:	https://cgjonline.ca/index.php/cgj/article/view/570
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!